SLC5A2 and myocardial infarction: Additionally, SGLT2 inhibitors have been shown to influence biomarkers such as leptin, ketone bodies, uric acid advanced glycation end‐products as well as ion transporters that have adverse effects on the myocardium and the vasculature through oxidative and inflammatory processes, resulting in deleterious consequences such as myocardial fibrosis, ventricular remodelling and arterial stiffness, increasing the risk of coronary artery disease, myocardial infarction, arrhythmogenesis and heart failure.11